vs
Side-by-side financial comparison of CALLAN JMB INC. (CJMB) and Q32 Bio Inc. (QTTB). Click either name above to swap in a different company.
Q32 Bio Inc. is the larger business by last-quarter revenue ($1.9M vs $1.2M, roughly 1.7× CALLAN JMB INC.). Q32 Bio Inc. runs the higher net margin — 2991.2% vs -223.8%, a 3215.0% gap on every dollar of revenue.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing targeted antibody-based immunotherapies for autoimmune disorders, inflammatory conditions and rare immunological diseases with unmet medical needs, operating primarily across North America and European markets.
CJMB vs QTTB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.9M |
| Net Profit | $-2.6M | $57.7M |
| Gross Margin | 30.3% | — |
| Operating Margin | -216.6% | — |
| Net Margin | -223.8% | 2991.2% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 506.9% |
| EPS (diluted) | $-0.58 | $4.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $1.9M | ||
| Q3 25 | $1.4M | $-220.0K | ||
| Q2 25 | $1.7M | $-284.0K | ||
| Q1 25 | $1.4M | $-371.0K | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-2.6M | $57.7M | ||
| Q3 25 | $-2.7M | $-7.4M | ||
| Q2 25 | $-1.4M | $-9.5M | ||
| Q1 25 | $-1.2M | $-11.0M | ||
| Q4 24 | — | $-14.2M | ||
| Q3 24 | — | $-17.6M | ||
| Q2 24 | — | $-17.0M | ||
| Q1 24 | — | $1.0M |
| Q4 25 | 30.3% | — | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 38.6% | — | ||
| Q1 25 | 42.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -216.6% | — | ||
| Q3 25 | -129.9% | 3444.1% | ||
| Q2 25 | -84.2% | 3229.2% | ||
| Q1 25 | -85.4% | 3296.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -223.8% | 2991.2% | ||
| Q3 25 | -188.8% | 3358.6% | ||
| Q2 25 | -83.9% | 3341.2% | ||
| Q1 25 | -85.6% | 2973.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-0.58 | $4.70 | ||
| Q3 25 | $-0.61 | $-0.60 | ||
| Q2 25 | $-0.31 | $-0.78 | ||
| Q1 25 | $-0.32 | $-0.90 | ||
| Q4 24 | — | $2.63 | ||
| Q3 24 | — | $-1.46 | ||
| Q2 24 | — | $-1.42 | ||
| Q1 24 | — | $-6.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $48.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3M | $42.0M |
| Total Assets | $5.8M | $61.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $48.3M | ||
| Q3 25 | $2.8M | $49.0M | ||
| Q2 25 | $4.2M | $54.8M | ||
| Q1 25 | $5.2M | $65.5M | ||
| Q4 24 | — | $78.0M | ||
| Q3 24 | — | $89.1M | ||
| Q2 24 | — | $97.7M | ||
| Q1 24 | — | $115.5M |
| Q4 25 | $2.3M | $42.0M | ||
| Q3 25 | $4.2M | $-18.4M | ||
| Q2 25 | $5.8M | $-12.2M | ||
| Q1 25 | $6.8M | $-4.0M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $18.3M | ||
| Q2 24 | — | $33.5M | ||
| Q1 24 | — | $48.8M |
| Q4 25 | $5.8M | $61.8M | ||
| Q3 25 | $7.7M | $57.8M | ||
| Q2 25 | $9.0M | $66.1M | ||
| Q1 25 | $8.5M | $79.1M | ||
| Q4 24 | — | $92.3M | ||
| Q3 24 | — | $104.5M | ||
| Q2 24 | — | $124.2M | ||
| Q1 24 | — | $152.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-659.0K | $-6.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | -0.11× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-659.0K | $-6.2M | ||
| Q3 25 | $-1.8M | $-4.2M | ||
| Q2 25 | $-563.3K | $-10.7M | ||
| Q1 25 | $-1.6M | $-12.5M | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $-19.5M | ||
| Q2 24 | — | $-22.2M | ||
| Q1 24 | — | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-995.8K | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $-19.6M | ||
| Q2 24 | — | $-22.2M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -133.5% | — | ||
| Q2 25 | -59.8% | — | ||
| Q1 25 | -108.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 11.7% | 0.0% | ||
| Q2 25 | 26.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.11× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -14.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CJMB
| Governmental | $1.1M | 91% |
| Other | $106.5K | 9% |
QTTB
Segment breakdown not available.
